Brief: Ionis Pharmaceuticals Inc - Zilganersen 50 Mg Meets Primary Endpoint, Stabilizes Gait Speed In Patients ≥5 Years At Week 61
21/04/2026 13:02
April 21 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS PHARMACEUTICALS INC - ZILGANERSEN 50 MG MEETS PRIMARY ENDPOINT, STABILIZES GAIT SPEED IN PATIENTS ≥5 YEARS AT WEEK 61 IONIS PHARMACEUTICALS INC - KEY SECONDARY ENDPOINT RESULTS CONSISTENTLY FAVORED ZILGANERSEN OVER CONTROL IONIS PHARMACEUTICALS INC - ZILGANERSEN UNDER FDA PRIORITY REVIEW WITH PDUFA DATE SET FOR SEPTEMBER 22, 2026 Source text: ID:nBw64D5kma Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study